You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CRISPR-Cas9

Showing 1 - 25 of 478
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Viral Keratitis, Blindness Eye, Herpes Simplex Virus Infection Trial in Shanghai (BD111 Adult single group Dose)

Completed
  • Viral Keratitis
  • +3 more
  • BD111 Adult single group Dose
  • Shanghai, Shanghai, China
    Eye & Ent Hospital of Fudan University
Aug 20, 2022

Gene Editing as a Therapeutic Approach for Rett Syndrome

Recruiting
  • Rett Syndrome
  • Gene editing in vitro
  • Siena, Italy
    University of Siena
Feb 13, 2023

Carbapenem-Resistant Enterobacteriaceae Infection Trial in Jinan (CAZ/AVI plus Aztreonam, Conventional treatment)

Recruiting
  • Carbapenem-Resistant Enterobacteriaceae Infection
  • CAZ/AVI plus Aztreonam
  • Conventional treatment
  • Jinan, Shandong, China
    Mingju Hao
Apr 29, 2023

Beta-Thalassemia, Thalassemia, Hematologic Diseases Trial (CTX001)

Not yet recruiting
  • Beta-Thalassemia
  • +6 more
  • CTX001
  • (no location specified)
Jul 26, 2022

Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma Trial in Nashville (CTX131)

Recruiting
  • Clear Cell Renal Cell Carcinoma
  • +4 more
  • CTX131
  • Nashville, Tennessee
    Research Site 1
Mar 21, 2023

Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn Trial in Worldwide (CTX001)

Active, not recruiting
  • Beta-Thalassemia
  • +4 more
  • CTX001
  • Stanford, California
  • +11 more
Nov 30, 2022

COVID-19 Respiratory Infection Trial (PD-1 and ACE2 Knockout T Cells)

Not yet recruiting
  • COVID-19 Respiratory Infection
  • PD-1 and ACE2 Knockout T Cells
  • (no location specified)
Aug 13, 2021

Transfusion Dependent Beta-Thalassaemia Trial in Guangzhou, Shenzhen, Tianjin (ET-01)

Active, not recruiting
  • Transfusion Dependent Beta-Thalassaemia
  • ET-01
  • Guangzhou, Guangdong, China
  • +3 more
May 9, 2022

Relapsed/Refractory Acute Myeloid Leukemia (AML) Trial in Dresden, Heidelberg (Donor-derived CD34+ HSC with CRISPR/Cas9-mediated

Not yet recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia (AML)
  • Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion
  • Gemtuzumab Ozogamicin
  • Dresden, Germany
  • +1 more
Dec 20, 2022

NSCLC, Metastatic Non Small Cell Lung Cancer, Stage IV NSCLC Trial in Duarte, Minneapolis (Fludarabine, Cyclophosphamide, CISH

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +5 more
  • Duarte, California
  • +1 more
Dec 7, 2022

B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy Trial (CTX112)

Not yet recruiting
  • B-cell Lymphoma
  • +7 more
  • CTX112
  • (no location specified)
Dec 12, 2022

A Long-term Follow-up Study in Subjects Who Received CTX001

Enrolling by invitation
  • Beta-Thalassemia
  • +6 more
  • CTX001
  • New York, New York
  • +12 more
Nov 18, 2022

Gastrointestinal Epithelial Cancer, Gastrointestinal Tumors, Cancer of Gastrointestinal Tract Trial in Minneapolis

Recruiting
  • Gastrointestinal Epithelial Cancer
  • +10 more
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Aug 20, 2021

T Cell Lymphoma Trial in Australia, Canada, United States (CTX130)

Recruiting
  • T Cell Lymphoma
  • CTX130
  • Duarte, California
  • +9 more
May 16, 2022

Multiple Myeloma Trial in Worldwide (CTX120)

Active, not recruiting
  • Multiple Myeloma
  • CTX120
  • Chicago, Illinois
  • +9 more
Jul 14, 2022

Solid Tumor, Adult Trial in Beijing (anti-mesothelin CAR-T cells)

Unknown status
  • Solid Tumor, Adult
  • anti-mesothelin CAR-T cells
  • Beijing, China
    Biotherapeutic Department and Hematology Department of Chinese P
Aug 6, 2020

Thalassemia, Beta, Thalassemia Major Trial in Tianjin (VGB-Ex01)

Not yet recruiting
  • Thalassemia, Beta
  • Thalassemia Major
  • VGB-Ex01
  • Tianjin, Tianjin, China
    Regenerative Medicine Center
Sep 11, 2023

Sickle Cell Disease Trial in Los Angeles, Oakland (CRISPR_SCD001)

Not yet recruiting
  • Sickle Cell Disease
  • Los Angeles, California
  • +1 more
Apr 25, 2022

B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma Trial in Worldwide (CTX110)

Recruiting
  • B-cell Malignancy
  • +3 more
  • CTX110
  • Los Angeles, California
  • +27 more
May 6, 2022

Neovascular Age-related Macular Degeneration(nAMD) Trial in Shanghai, Tianjin (HG202)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration(nAMD)
  • HG202
  • Shanghai, Shanghai, China
  • +1 more
Sep 4, 2023

Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn Trial in Nashville (CTX001)

Recruiting
  • Beta-Thalassemia
  • +4 more
  • CTX001
  • Nashville, Tennessee
  • +5 more
Feb 2, 2023

Beta-Thalassemia Trial in China (BRL-101)

Recruiting
  • Beta-Thalassemia
  • Guangzhou, Guangdong, China
  • +3 more
Nov 7, 2022

Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance Trial in Nashville (CTX001)

Recruiting
  • Sickle Cell Disease
  • +4 more
  • CTX001
  • Philadelphia, Pennsylvania
  • +3 more
Jan 24, 2023

Severe Pneumonia Trial in Changzhou, Nanjing, Suzhou (SSBD(PCR-CRISPR/Cas12a))

Not yet recruiting
  • Severe Pneumonia
  • SSBD(PCR-CRISPR/Cas12a)
  • Changzhou, Jiangsu, China
  • +4 more
May 8, 2022

Glioblastoma Trial in Milwaukee (Gallium maltolate (500 mg), Gallium maltolate (1,000 mg), Gallium maltolate (1,500 mg))

Recruiting
  • Glioblastoma
  • Gallium maltolate (500 mg)
  • +3 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & the Medical College of Wisconsin
Sep 20, 2022